Nowadays, the prevalence of Multiple Myeloma (MM) seems to have been increasing among young females. Here, we report that thalidomide is contraindicated in pregnant women diagnosed with MM and those desirous of subsequent pregnancy. In this case report, we compared the clinical response of ThalidomideDexamethasone therapy in a post-abortive woman with persistently elevated β-hCG levels due to retained products of conception, undergoing hysterectomy later. This case report underlines the clinical significance of age, the effect of Thalidomide-Dexamethasone therapy even after initial discontinuation and the response to high β-hCG levels.
INTRODUCTION
Multiple myeloma is a neoplasm affecting bone marrow due to uncontrolled growth of plasma cells. The median age for diagnosis of multiple myeloma is 70 years and has a male predilection. Multiple myeloma in a woman of childbearing age is uncommon and the disease has a rapid downhill course 1 . Thalidomide dexamethasone therapy has proven useful and effective in the treatment of advanced and refractory myeloma, both as a primary and second-line treatment, with a high response rate and acceptable survival 2 . The main related complications are cytopenias, deep vein thrombosis, dry skin, constipation and paresthesia which require close monitoring 2.3,4 . Pregnancy is an absolute contraindication due to its teratogenic effects 5 .
Here, we present a case of a 32-year-old postabortive female who was started on ThalidomideDexamethasone therapy, but the regimen had to be discontinued due to retained products of conception. The effective response was still possible by restarting the treatment with same drugs after the patient underwent hysterectomy as an absolute method of contraception.
Case report
A 32-year-old female presented to the gynecology department in JNMCH, AMU, Aligarh, India with eight weeks amenorrhoea, generalized body ache and painful gait. The patient was G4P3+0 L3, apparently normal, except for the pain in the last showed multiple ill-defined lytic lesions with no definitive sclerosis. There was decreased height of vertebral body suggestive of collapse from T8, T11 and L1 to L4. X-Ray Skull Lateral view: showed multiple variable sized, ill-defined lytic areas involving the calvarium. X-Ray Pelvis with both hips AP view: showed multiple lytic lesions in left subtrochanteric region ( Figure 1 ). showing a progesterone level of 6.9 ng/ml, estrogen 25 ng/ml and β HCG 12 mIU/ml. A suspicion of pregnancy or associated neoplastic complications was aroused; the treatment was stopped and the patient thoroughly investigated with endometrial biopsy, but no obvious cause was found.
The patient was convinced to undergo a total hysterectomy. Histopathological examination revealed retained products of conception, showing degenerating villi and hemmorrhage. After two weeks, β-hCG was not detectable in serum or urine, and other hormone levels were within normal limits. The patient was monitored for two months and treated conservatively. ThalidomideDexamethasone regimen restarted in a dose of 250 mg /day and 40mg for 4 days a week, respectively, and the response was monitored using the parameters described previously. After 10 weeks of therapy, Bence-Jones proteinuria was absent, serum calcium was 9.8 mg/dl, plasma cells decreased in bone marrow aspirate, no new lesion was detected on radiological examination, no worsening of clinical signs and symptoms was seen and no considerable relief in pain was gained. The patient was on the same regimen and had monthly routine health checkups within the past 6 months.
DISCUSSION
Multiple myeloma is characterized by malignant clone of plasma cells invading bone marrow. The patient had a marrow plasmacytosis of 40%, serum IgG component of 5.09 gm/dl, Bence-Jones proteinuria along with multiple lytic bone lesions on X-ray, thereby satisfying two major criteria and one minor criterion for the diagnosis of Multiple Myeloma
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. Based on these criteria in a clinical setting of symptomatic disease, the patient was diagnosed with multiple myeloma. Previous reports have documented cases of multiple myeloma during pregnancy, one such report documenting a live child birth. The treatment of multiple myeloma during pregnancy has always been a dilemma, and the role of newer agents like interferon, thalidomide and lenalidomide warrants termination of pregnancy. Thalidomide guidelines clearly indicate that it should not be taken during pregnancy and there must be at least two contraceptive methods
5
. The failure rate for termination of pregnancy using vacuum evacuation is less than 1%, and complications like incomplete evacuation, perforation and excessive bleeding have rarely been reported 7 . Unfortunately, this complication happened in our case and she ultimately underwent hysterectomy. The role of dexamethasone-thalidomide regimen in inducing remission in newly diagnosed multiple myeloma patients have been reported to be 63% by Rajkumar et al. 8 .Similarly, advanced and refractory myeloma has shown better results with thalidomide 2,9 . Our patient had advanced myeloma and though the drug was discontinued due to retained products of conception, restarting the drug after two months of hysterectomy ensured a significant improvement. The hormones estrogen and progesterone are normally present in a woman, albeit in varying proportions, but β-hCG is linked to pregnancy and gestational trophoblastic diseases. The role of β-hCG as a detrimental factor in achieving a full and effective thalidomide-dexamethasone treatment needs to be evaluated with further studies.
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